InsiderTrades

Form 4 for ATYR aTYR PHARMA INC

Accepted 2025-02-04 00:00:00 ET · period of report 2025-02-03 · accession 0000950170-25-013878 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2025-02-04 2025-02-03 ATYR DENYES NANCY GC M - OptEx — +2,687 27.5K +11% —
D 2025-02-04 2025-02-04 ATYR DENYES NANCY GC S - Sale+OE $3.78 -899 26.6K -3% -$3,398
D 2025-02-04 2025-02-03 ATYR DENYES NANCY GC M - OptEx $0.00 -2,687 2,687 -50% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2025-02-03 M A 2,687 — 27,454 D — — (F2) Restricted stock units convert into common stock on a one-for-one basis. (F3) Includes 2,500 shares acquired on November 15, 2024 under the Company's 2015 Employee Purchase Plan.
2 Common Common Stock 2025-02-04 S D 899 $3.78 26,555 D — —
3 Derivative Restricted Stock Unit 2025-02-03 M D 2,687 $0.00 2,687 D — · — to — 2,687 Common Stock (F2) Restricted stock units convert into common stock on a one-for-one basis. (F5) The RSUs vest in four equal annual installments beginning on February 3, 2023, such that the RSUs will fully vest on February 3, 2026. The RSUs are subject to accelerated vesting upon termination without cause upon a change of control of the Issuer.